Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Rob White

- PMLiVE

NICE won’t back early use of Zytiga in prostate cancer

Says Janssen drug should not be used prior to chemotherapy

Oncology drugs under AMNOG: part one

Segmentation and comparator choice - lessons for cancer drug market access in Germany

- PMLiVE

Following the biologic path

Biosimilar regulations in Canada, the US and Europe all have a degree of uncertainty

- PMLiVE

Boehringer lines up biosimilars of major drugs

Prospects include copies of Humira, Avastin and MabThera

National Institute for Health and Care Excellence NICE logo

NICE gives partial backing to Ferring’s prostate cancer drug

Firmagon on course for use on NHS in England and Wales

- PMLiVE

Herceptin could face biosimilars in UK later this year

Court overturns patents protecting Roche’s cancer drug

- PMLiVE

Interview: Georg Toufar, Mundipharma

Mundipharma’s chief marketing officer Georg Toufar on the benefits of having a smaller, more concentrated focus

National Institute for Health and Care Excellence NICE logo

NICE consults on value-based assessment changes

Aims to create a more flexible approach to drug funding decisions for NHS in England and Wales

Lilly launches online training to boost patient voice in HTA

New tool aims to help patient advocates 'better influence decisions'

- PMLiVE

Ireland and the impact of reference pricing

Industry remains tight-lipped on the country's pharmaceutical pricing changes

- PMLiVE

No price ceiling for rare disease drugs, say MPs

BIA survey comes ahead of consultation on evaluation framework for ultra-orphans

NICE and ‘ultra orphans’

NICE and its processes for ‘highly specialised therapies’

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links